Hatzis-Schoch Brent 4
4 · Black Diamond Therapeutics, Inc. · Filed Mar 16, 2021
Insider Transaction Report
Form 4
Hatzis-Schoch Brent
SEE REMARKS
Transactions
- Sale
Common Stock
2021-03-12$26.36/sh−4,078$107,493→ 8,400 total - Exercise/Conversion
Common Stock
2021-03-12$3.20/sh+4,078$13,050→ 12,478 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-03-12−4,078→ 168,630 totalExercise: $3.20Exp: 2029-06-11→ Common Stock (4,078 underlying)
Footnotes (3)
- [F1]Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.8375 to $26.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter.